1. Participants ≥18 years of age (or the minimum country specific age of consent if >18) at the screening visit. WOCBP may be enrolled. All fertile participants must agree to use a highly effective method of contraception. 2. Participants who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures. 3.Participants who have a negative screening SARS-CoV-2 rapid antigen test result and who are asymptomatic household contacts (ie, living in the same residence, see Appendix 13) of an individual who is symptomatic and recently tested positive for SARS-CoV-2 (ie, index case: patient with symptomatic COVID-19). To be included in the study, participants must be randomized within 24 hours of their negative SARS-CoV-2 rapid antigen test and within 96 hours of collection of the index case's first positive SARS-CoV-2 test. Note: The index case will have confirmation of SARS-CoV-2 infection by RT-PCR or other molecular or antigen tests that detect viral RNA or protein (see Section 8.1.5). Note: Participants with a negative screening SARS-CoV-2 local rapid antigen test result and whose baseline RT-PCR result is returned as positive would be allowed to remain on treatment in the study. Note: Asymptomatic is defined as having no signs/symptoms consistent with COVID-19 and symptomatic is defined as having at least 1 of the specified signs or symptoms consistent with COVID-19 (see Appendix 9). 4. Capable of giving signed informed consent as described in Appendix 1, which includes compliance with the requirements and restrictions listed in the ICD and in this protocol.

1. Participants ≥18 years of age (or the minimum country specific age of consent if >18) at the screening visit. WOCBP may be enrolled. All fertile participants must agree to use a highly effective method of contraception. 2. Participants who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures. 3.Participants who have a negative screening SARS-CoV-2 rapid antigen test result and who are asymptomatic household contacts (ie, living in the same residence, see Appendix 13) of an individual who is symptomatic and recently tested positive for SARS-CoV-2 (ie, index case: patient with symptomatic COVID-19). To be included in the study, participants must be randomized within 24 hours of their negative SARS-CoV-2 rapid antigen test and within 96 hours of collection of the index case's first positive SARS-CoV-2 test. Note: The index case will have confirmation of SARS-CoV-2 infection by RT-PCR or other molecular or antigen tests that detect viral RNA or protein (see Section 8.1.5). Note: Participants with a negative screening SARS-CoV-2 local rapid antigen test result and whose baseline RT-PCR result is returned as positive would be allowed to remain on treatment in the study. Note: Asymptomatic is defined as having no signs/symptoms consistent with COVID-19 and symptomatic is defined as having at least 1 of the specified signs or symptoms consistent with COVID-19 (see Appendix 9). 4. Capable of giving signed informed consent as described in Appendix 1, which includes compliance with the requirements and restrictions listed in the ICD and in this protocol.